BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21095548)

  • 1. Nutrition and gastroenteropancreatic neuroendocrine tumors.
    Go VL; Srihari P; Kamerman Burns LA
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):827-37. PubMed ID: 21095548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms.
    Briest F; Grabowski P
    Cancer Treat Rev; 2015 May; 41(5):423-30. PubMed ID: 25837868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
    Lindholm DP; Oberg K
    Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutritional Complications and the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Laing E; Kiss N; Michael M; Krishnasamy M
    Neuroendocrinology; 2020; 110(5):430-442. PubMed ID: 31550712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
    Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
    Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetics of gastroenteropancreatic neuroendocrine tumors.
    Starker LF; Carling T
    Curr Opin Oncol; 2009 Jan; 21(1):29-33. PubMed ID: 19125015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroenteropancreatic endocrine tumors.
    Meeker A; Heaphy C
    Mol Cell Endocrinol; 2014 Apr; 386(1-2):101-20. PubMed ID: 23906538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?
    Fottner C; Ferrata M; Weber MM
    Rev Endocr Metab Disord; 2017 Dec; 18(4):393-410. PubMed ID: 29256148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A; Bhatt V
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroenteropancreatic neuroendocrine tumours.
    Modlin IM; Oberg K; Chung DC; Jensen RT; de Herder WW; Thakker RV; Caplin M; Delle Fave G; Kaltsas GA; Krenning EP; Moss SF; Nilsson O; Rindi G; Salazar R; Ruszniewski P; Sundin A
    Lancet Oncol; 2008 Jan; 9(1):61-72. PubMed ID: 18177818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?
    Grande E; Capdevila J; Barriuso J; Antón-Aparicio L; Castellano D
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):47-53. PubMed ID: 22105614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site- and grade-specific diversity of LINE1 methylation pattern in gastroenteropancreatic neuroendocrine tumours.
    Stricker I; Tzivras D; Nambiar S; Wulf J; Liffers ST; Vogt M; Verdoodt B; Tannapfel A; Mirmohammadsadegh A
    Anticancer Res; 2012 Sep; 32(9):3699-706. PubMed ID: 22993308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors.
    Berković M; Cacev T; Zjacić-Rotkvić V; Kapitanović S
    Neuroendocrinology; 2006; 84(5):346-52. PubMed ID: 17164537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of neuroendocrine tumours: A nutritional viewpoint.
    Gallo M; Muscogiuri G; Pizza G; Ruggeri RM; Barrea L; Faggiano A; Colao A;
    Crit Rev Food Sci Nutr; 2019; 59(7):1046-1057. PubMed ID: 29020456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polypeptide growth factors in gastroenteropancreatic neuroendocrine tumours.
    Blicharz-Dorniak J; Kos-Kudła B; Kudła M; Foltyn W; Marek B; Siemińska L; Nowak M
    Endokrynol Pol; 2007; 58(1):42-9. PubMed ID: 17354204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on gastroenteropancreatic neuroendocrine tumors.
    Cives M; Strosberg J
    Oncology (Williston Park); 2014 Sep; 28(9):749-56, 758. PubMed ID: 25224471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic therapy of gastroenteropancreatic (GEP) tumors.
    Syrigos KN; Sitara D; Georgiou E; Harrington KJ
    Anticancer Res; 2002; 22(2B):1311-4. PubMed ID: 12168943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.